Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to -$0.19.

  • Sunshine Biopharma's EPS (Basic) rose 7978.72% to -$0.19 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.27, marking a year-over-year increase of 10534.86%. This contributed to the annual value of -$7.32 for FY2024, which is 9791.77% up from last year.
  • As of Q3 2025, Sunshine Biopharma's EPS (Basic) stood at -$0.19, which was up 7978.72% from -$0.39 recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's EPS (Basic) peaked at $0.26 during Q4 2021, and registered a low of -$97.47 during Q4 2023.
  • In the last 5 years, Sunshine Biopharma's EPS (Basic) had a median value of -$1.55 in 2022 and averaged -$13.22.
  • In the last 5 years, Sunshine Biopharma's EPS (Basic) soared by 10938.96% in 2021 and then tumbled by 20922804.01% in 2023.
  • Quarter analysis of 5 years shows Sunshine Biopharma's EPS (Basic) stood at $0.26 in 2021, then crashed by 706.43% to -$1.55 in 2022, then tumbled by 6193.06% to -$97.47 in 2023, then skyrocketed by 96.84% to -$3.08 in 2024, then surged by 93.82% to -$0.19 in 2025.
  • Its EPS (Basic) was -$0.19 in Q3 2025, compared to -$0.39 in Q2 2025 and -$0.44 in Q1 2025.